Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Hepatology Reports
Erschienen in: Current Hepatology Reports 1/2017

23.01.2017 | Hepatic Cancer (A Singal and A Mufti, Section Editors)

Changes in Liver Transplant Criteria for Hepatocellular Carcinoma

verfasst von: Dekey Lhewa, Neehar D. Parikh

Erschienen in: Current Hepatology Reports | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

There have been several recent policy changes in liver transplantation for hepatocellular carcinoma (HCC). We outline the most recent changes in allocation policy for HCC prior to transplant and the rationale behind them.

Recent Findings

The United Network for Organ Sharing recently adopted a new allocation policy for HCC to better balance organ availability between HCC and non-HCC waitlist candidates and exclude patients with rapidly progressive HCC. This policy includes a mandatory 6-month waiting period prior to application of model for end-stage liver disease (MELD) exception points and a cap of 34 points.

Summary

The new policies have changed the landscape of liver transplantation for HCC in the USA. The allocation policy should better select HCC patients who would have the best post-transplant outcome and balance liver transplant benefits between HCC and non-HCC patients.
Literatur
1.•
Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–37. An important epidemiologic study which showed that liver cancer is increasing in incidence in the United States.CrossRefPubMed
2.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.CrossRefPubMed
3.
Washburn K, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant. 2010;10(7):1643–8.CrossRefPubMed
4.
Goldberg D, French B, Abt P, Feng S, Cameron AM. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl. 2012;18(4):434–43.CrossRefPubMed
5.
Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991;15(2):270–85.CrossRefPubMed
6.
Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993;218(2):145–51.CrossRefPubMedPubMedCentral
7.
Bismuth H, Chiche L. Comparison of hepatic resection and transplantation in the treatment of liver cancer. Semin Surg Oncol. 1993;9(4):341–5.CrossRefPubMed
8.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.CrossRefPubMed
9.
Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 2004;10(7):911–8.CrossRefPubMed
10.
Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44–57.CrossRefPubMed
11.
Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology. 2004;127(5 Suppl 1):S261–7.CrossRefPubMed
12.
Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl. 2003;9(7):684–92.CrossRefPubMed
13.
Hayashi PH, Trotter JF, Forman L, Kugelmas M, Steinberg T, Russ P, et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl. 2004;10(1):42–8.CrossRefPubMed
14.••
Heimbach JK, Hirose R, Stock PG, Schladt DP, Xiong H, Liu J, et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology. 2015;61(5):1643–50. This modeling study showed that a 6-9 month waiting period prior to granting a MELD exception for listed patients with HCC decreased the transplant disparity between HCC candidates and non-HCC candidates.CrossRefPubMedPubMedCentral
15.
Massie AB, Chow EK, Wickliffe CE, Luo X, Gentry SE, Mulligan DC, et al. Early changes in liver distribution following implementation of share 35. Am J Transplant. 2015;15(3):659–67.CrossRefPubMed
16.
Sotiropoulos GC, Molmenti EP, Losch C, Beckebaum S, Broelsch CE, Lang H. Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases. Eur J Med Res. 2007;12(10):527–34.PubMed
17.
Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7(11):2587–96.CrossRefPubMed
18.
Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl. 2015;21(9):1142–52.CrossRefPubMed
19.
Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, et al. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma. Clin Transpl. 2012;26(4):E359–64.CrossRef
20.
Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013;19(12):1343–53.CrossRefPubMed
21.
Halazun KJ, Patzer RE, Rana AA, Verna EC, Griesemer AD, Parsons RF, et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology. 2014;60(6):1957–62.CrossRefPubMed
22.•
Mehta N, Heimbach J, Harnois DM, Dodge JL, Burns JM, Lee D, et al. Short waiting time predicts early recurrence of hepatocellular carcinoma after liver transplantation: a multicenter study supporting the “ablate and wait” principle. Boston: The Liver Meeting; 2014. This study established the criteria that predicts low risk of dropout for patients with HCC: response to locoregional therapy and low AFP level.
23.
Kim YS, Lim HK, Rhim H, Lee WJ, Joh JW, Park CK. Recurrence of hepatocellular carcinoma after liver transplantation: patterns and prognostic factors based on clinical and radiologic features. AJR Am J Roentgenol. 2007;189(2):352–8.CrossRefPubMed
24.
Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10(4):534–40.CrossRefPubMed
25.
Escartin A, Sapisochin G, Bilbao I, Vilallonga R, Bueno J, Castells L, et al. Recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2007;39(7):2308–10.CrossRefPubMed
26.
Hiraoka A, Horiike N, Yamashita Y, Koizumi Y, Doi K, Yamamoto Y, et al. Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications. Hepatogastroenterology. 2008;55(88):2171–4.PubMed
27.•
Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20(8):945–51. This study showed that a very high AFP can be highly predictive of vascular invasion and thus may be considered an exclusion criteria for liver transplantation.CrossRefPubMedPubMedCentral
28.
Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10(1):129–37.CrossRefPubMed
29.
de Mattos AA, dos Santos Schraiber L, Zanotell ML, Cantisani G. Is there an ideal cutoff for alpha-fetoprotein as an exclusion criterion for liver transplantation? Liver Transpl. 2014;20(10):1284.CrossRefPubMed
30.
Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl. 2013;19(6):634–45.CrossRefPubMed
31.
Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13(1):e11–22.CrossRefPubMed
32.
Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: an adaptive approach. Hepatology. 2016;63(5):1707–17.CrossRefPubMedPubMedCentral
33.
Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma—a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther. 2014;40(8):893–902.CrossRefPubMed
34.••
Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64(6):2077–88. This is the first prospective study that validates the extended Toronto criteria for liver transplantation.CrossRefPubMed
35.
Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968–77.CrossRefPubMedPubMedCentral
Metadaten
Titel
Changes in Liver Transplant Criteria for Hepatocellular Carcinoma
verfasst von
Dekey Lhewa
Neehar D. Parikh
Publikationsdatum
23.01.2017
Verlag
Springer US
Erschienen in
Current Hepatology Reports / Ausgabe 1/2017
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-017-0330-5

Weitere Artikel der Ausgabe 1/2017

Current Hepatology Reports 1/2017 Zur Ausgabe

Hepatic Cancer (A Singal and A Mufti, Section Editors)

NAFLD-Related HCC: How Should the Shift in Epidemiology Change Our Prevention and Surveillance Strategies?

Hepatitis C (J Ahn and A Aronsohn, Section Editors)

Use of Hepatitis C-Positive Donor Livers in Liver Transplantation

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated?

Hepatitis C (J Ahn and A Aronsohn, Section Editors)

Future Paradigms of HCV Management with Resistance Testing

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Advances in Pediatric Liver Tumors

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Liver Biopsy for Hepatocellular Carcinoma (HCC): Should this be a Routine?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise